Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Long-acting Injectable Antipsychotics and Stigma: Some Considerations and Future Perspectives

Author(s): Antimo Natale, Laura Fusar-Poli, Andrea Amerio, Andrea Escelsior, Gianluca Serafini, Eugenio Aguglia, Mario Amore and Andrea Aguglia*

Volume 29, Issue 13, 2023

Published on: 18 April, 2023

Page: [981 - 983] Pages: 3

DOI: 10.2174/1381612829666230406102039

Price: $65

conference banner
« Previous
[1]
Vieta E, Berk M, Schulze TG, et al. Bipolar disorders. Nat Rev Dis Primers 2018; 4(1): 18008.
[http://dx.doi.org/10.1038/nrdp.2018.8] [PMID: 29516993]
[2]
Correll CU. Using patient-centered assessment in schizophrenia care: Defining recovery and discussing concerns and preferences. J Clin Psychiatry 2020; 81(3): MS19053BR2C.
[http://dx.doi.org/10.4088/JCP.MS19053BR2C]
[3]
Emsley R, Chiliza B, Asmal L, Harvey BH. The nature of relapse in schizophrenia. BMC Psychiatry 2013; 13(1): 50.
[http://dx.doi.org/10.1186/1471-244X-13-50] [PMID: 23394123]
[4]
Emsley R, Nuamah I, Hough D, Gopal S. Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophr Res 2012; 138(1): 29-34.
[http://dx.doi.org/10.1016/j.schres.2012.02.030] [PMID: 22446143]
[5]
Czobor P, Van Dorn RA, Citrome L, Kahn RS, Fleischhacker WW, Volavka J. Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST studies. Eur Neuropsychopharmacol 2015; 25(8): 1158-66.
[http://dx.doi.org/10.1016/j.euroneuro.2015.04.003] [PMID: 26004980]
[6]
Takeuchi H, Siu C, Remington G, et al. Does relapse contribute to treatment resistance? Antipsychotic response in first vs. second-episode schizophrenia. Neuropsychopharmacology 2019; 44(6): 1036-42.
[http://dx.doi.org/10.1038/s41386-018-0278-3] [PMID: 30514883]
[7]
Shimomura Y, Kikuchi Y, Suzuki T, Uchida H, Mimura M, Takeuchi H. Antipsychotic treatment in the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms. Schizophr Res 2020; 215: 8-16.
[http://dx.doi.org/10.1016/j.schres.2019.09.013] [PMID: 31784340]
[8]
Kishi T, Ikuta T, Matsuda Y, et al. Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: A systematic review and network meta-analysis of randomized controlled trials. Mol Psychiatry 2021; 26(8): 4146-57.
[http://dx.doi.org/10.1038/s41380-020-00946-6] [PMID: 33177610]
[9]
de Filippis R, De Fazio P, Gaetano R, et al. Current and emerging long-acting antipsychotics for the treatment of schizophrenia. Expert Opin Drug Saf 2021; 20(7): 771-90.
[http://dx.doi.org/10.1080/14740338.2021.1910674] [PMID: 33775184]
[10]
Riboldi I, Cavaleri D, Capogrosso CA, Crocamo C, Bartoli F, Carrà G. Practical guidance for the use of long-acting injectable antipsychotics in the treatment of schizophrenia. Psychol Res Behav Manag 2022; 15: 3915-29.
[http://dx.doi.org/10.2147/PRBM.S371991] [PMID: 36605176]
[11]
Ostuzzi G, Bertolini F, Del Giovane C, et al. Maintenance treatment with long-acting injectable antipsychotics for people with nonaffective psychoses: A network meta-analysis. Am J Psychiatry 2021; 178(5): 424-36.
[http://dx.doi.org/10.1176/appi.ajp.2020.20071120] [PMID: 33596679]
[12]
Ostuzzi G, Bertolini F, Tedeschi F, et al. Oral and long‐acting antipsychotics for relapse prevention in schizophrenia‐spectrum disorders: A network meta‐analysis of 92 randomized trials including 22,645 participants. World Psychiatry 2022; 21(2): 295-307.
[http://dx.doi.org/10.1002/wps.20972] [PMID: 35524620]
[13]
Pacchiarotti I, Tiihonen J, Kotzalidis GD, et al. Long-Acting Injectable Antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review. Eur Neuropsychopharmacol 2019; 29(4): 457-70.
[http://dx.doi.org/10.1016/j.euroneuro.2019.02.003] [PMID: 30770235]
[14]
Aguglia A, Fusar-Poli L, Natale A, et al. Factors associated with medication adherence to long-acting injectable antipsychotics: Results from the star network depot study. Pharmacopsychiatry 2022; 55(6): 281-9.
[http://dx.doi.org/10.1055/a-1804-6211] [PMID: 35468642]
[15]
Brain C, Sameby B, Allerby K, et al. Stigma, discrimination and medication adherence in schizophrenia: Results from the Swedish COAST study. Psychiatry Res 2014; 220(3): 811-7.
[http://dx.doi.org/10.1016/j.psychres.2014.10.016] [PMID: 25457284]
[16]
Dubreucq J, Plasse J, Franck N. Self-stigma in serious mental illness: a systematic review of frequency, correlates, and consequences. Schizophr Bull 2021; 47(5): 1261-87.
[http://dx.doi.org/10.1093/schbul/sbaa181] [PMID: 33459793]
[17]
Yanos PT, Roe D, Markus K, Lysaker PH. Pathways between internalized stigma and outcomes related to recovery in schizophrenia spectrum disorders. Psychiatr Serv 2008; 59(12): 1437-42.
[http://dx.doi.org/10.1176/ps.2008.59.12.1437] [PMID: 19033171]
[18]
Wood L, Byrne R, Burke E, Enache G, Morrison AP. The impact of stigma on emotional distress and recovery from psychosis: The mediatory role of internalised shame and self-esteem. Psychiatry Res 2017; 255: 94-100.
[http://dx.doi.org/10.1016/j.psychres.2017.05.016] [PMID: 28531822]
[19]
Wei Y, McGrath P, Hayden J, Kutcher S. The quality of mental health literacy measurement tools evaluating the stigma of mental illness: A systematic review. Epidemiol Psychiatr Sci 2018; 27(5): 433-62.
[http://dx.doi.org/10.1017/S2045796017000178] [PMID: 28462747]
[20]
Thornicroft G, Brohan E, Rose D, Sartorius N, Leese M. Global pattern of experienced and anticipated discrimination against people with schizophrenia: A cross-sectional survey. Lancet 2009; 373(9661): 408-15.
[http://dx.doi.org/10.1016/S0140-6736(08)61817-6] [PMID: 19162314]
[21]
Carrara BS, Ventura CAA. Self-stigma, mentally ill persons and health services: An integrative review of literature. Arch Psychiatr Nurs 2018; 32(2): 317-24.
[http://dx.doi.org/10.1016/j.apnu.2017.11.001] [PMID: 29579531]
[22]
Martins MJRV, Pinto AM, Castilho P, et al. Assessing beliefs and attitudes towards antipsychotic medication from a recovery-based perspective: Psychometric properties of a new scale. Psychiatry Res 2019; 273: 325-30.
[http://dx.doi.org/10.1016/j.psychres.2019.01.043] [PMID: 30677722]
[23]
Barlati S, Morena D, Nibbio G, et al. Internalized stigma among people with schizophrenia: Relationship with socio-demographic, clinical and medication-related features. Schizophr Res 2022; 243: 364-71.
[http://dx.doi.org/10.1016/j.schres.2021.06.007] [PMID: 34183209]
[24]
Kerrigan D, Mantsios A, Gorgolas M, et al. Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain. PLoS One 2018; 13(1): e0190487.
[http://dx.doi.org/10.1371/journal.pone.0190487] [PMID: 29304154]
[25]
Sartorius N. Patient-reported outcomes in psychiatry. Dialogues Clin Neurosci 2014; 16(2): 123-4.
[http://dx.doi.org/10.31887/DCNS.2014.16.2/nsartorius] [PMID: 25152651]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy